<SEC-DOCUMENT>0001193125-15-281148.txt : 20150806
<SEC-HEADER>0001193125-15-281148.hdr.sgml : 20150806
<ACCEPTANCE-DATETIME>20150806164205
ACCESSION NUMBER:		0001193125-15-281148
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150806
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150806
DATE AS OF CHANGE:		20150806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		151033706

	BUSINESS ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE, SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE, SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d75328d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): August&nbsp;6, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GlycoMimetics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36177</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>06-1686563</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>9708 Medical Center Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Rockville, MD 20850 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(240) 243-1201 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.02 Results of Operations and Financial Condition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2015, GlycoMimetics, Inc. (the &#147;<B><I>Registrant</I></B>&#148; or the &#147;<B><I>Company</I></B>&#148;) issued a press
release announcing its financial results for the quarter ended June&nbsp;30, 2015. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with General Instruction B.2. of Form 8-K, the information in this Item&nbsp;2.02, and Exhibit 99.1 hereto, shall not be deemed
&#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by
reference in any of the Registrant&#146;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set
forth by specific reference in such a filing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated August 6, 2015, &#147;GlycoMimetics Reports Second Quarter 2015 Results.&#148;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>GLYCOMIMETICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian M. Hahn</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;6, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian M. Hahn</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated August 6, 2015, &#147;GlycoMimetics Reports Second Quarter 2015 Results.&#148;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d75328dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 99.1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g75328g34a30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLYCOMIMETICS REPORTS SECOND QUARTER 2015 RESULTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ROCKVILLE, MD, August&nbsp;6, 2015</B>&#150; GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the second quarter ended June&nbsp;30,
2015. As of June&nbsp;30, 2015, GlycoMimetics had cash and cash equivalents of $40.2 million. GlycoMimetics has also received a $20.0 million milestone payment from Pfizer upon the initiation of a Phase 3 clinical trial for rivipansel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Perhaps the single most important highlight of the quarter was the initiation of the Phase 3 rivipansel trial by our strategic partner, Pfizer,
Inc.,&#148; said Rachel King, CEO of GlycoMimetics. &#147;In June, we announced the dosing of the first patient in the RESET (<B>R</B>ivipansel: <B>E</B>valuating&nbsp;<B>S</B>afety,&nbsp;<B>E</B>fficacy and&nbsp;<B>T</B>ime to Discharge) trial - a
Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis (VOC) in patients hospitalized with sickle cell disease who are at least six years old. This triggered a $20 million milestone payment,
which we received after the close of the quarter. Recruitment of patients and clinical site initiations are ongoing, and we are looking toward the goal of bringing a paradigm-changing therapy to the underserved sickle cell patient population.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In addition to rivipansel, we have initiated a Phase 1/2 clinical trial to evaluate our wholly-owned drug candidate, GMI-1271, a novel and
proprietary E-selectin antagonist,&#148; Ms.&nbsp;King added. &#147;The ongoing trial is studying the safety, pharmacokinetics (PK) and efficacy of&nbsp;GMI-1271, when used in combination with chemotherapy in patients with acute myeloid leukemia
(AML).&nbsp;In May 2015, the&nbsp;U.S. Food and Drug Administration&nbsp;(FDA) granted Orphan Drug designation to&nbsp;this compound for the treatment of AML.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GlycoMimetics recorded revenue of $20.0 million during the quarter ended June&nbsp;30, 2015 versus $15.0 million in revenue for the quarter ended
June&nbsp;30, 2014. Revenue for the second quarter 2015 was due to the $20.0 million non-refundable milestone payment from Pfizer. The revenue received for the quarter ended June&nbsp;30, 2014 was based on the $15.0 million non-refundable milestone
payment received from Pfizer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company&#146;s research and development expenses increased to $7.8 million for the quarter ended June&nbsp;30, 2015 as
compared to $5.4 million for the second quarter of 2014. This increase reflects spending on manufacturing and process development of GMI-1271 and the costs of the Phase 1/2 clinical trial for which the company enrolled the first patient in May 2015.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company&#146;s general and administrative expenses increased to $1.8 million for the quarter ended June&nbsp;30, 2015 as compared to $1.6 million for
the second quarter of 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About GlycoMimetics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GlycoMimetics&nbsp;is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical
needs resulting from diseases in which </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
carbohydrate biology plays a key role. GlycoMimetics entered into an exclusive license agreement with Pfizer for rivipansel in October 2011. Under the license agreement, Pfizer is responsible for
the clinical development, regulatory approval and potential commercialization of rivipansel.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GlycoMimetics&#146;s&nbsp;wholly-owned drug candidate
(GMI-1271) for AML and other blood disorders is also in clinical trials. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of
carbohydrate biology,&nbsp;GlycoMimetics&nbsp;is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Learn more
at&nbsp;<U>www.glycomimetics.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements regarding the clinical development of the company&#146;s drug candidates and the presentation of data.
Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the
company&#146;s annual report on Form 10-K that was filed with the U.S. Securities and Exchange Commission on March&nbsp;16, 2015, and other filings the company makes with the SEC from time to time. Forward-looking statements speak only as of the
date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">#
# # </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: GlycoMimetics </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shari Annes </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone: 650-888-0902 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: sannes@annesassociates.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jamie Lacey-Moreira </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone: 410-299-3310 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: jamielacey@presscommpr.com </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GlycoMimetics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Condensed Statements of Operations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three months ended June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Six months ended June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(Unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(Unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost and Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income and comprehensive income before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income and net comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income per share &#150; basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income per share &#150; diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares &#150; basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,011,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,807,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,986,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,020,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares &#150; diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,236,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,238,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,227,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,472,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GlycoMimetics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Balance Sheet Data </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands)
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(Unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g75328g34a30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g75328g34a30.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M8W]E+)!=V[CE9(I&4]C1MY$;>5C2H * "@ H * "@ H * "@ H * "@ H *
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M699A<HPJPF$C)4^>4VYN\Y2D]Y-))\J481T7NQ5[N[?25PGH!0 4 % !0 4
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M/%^@:/XF\/:I%Y.HZ)KNGVNJ:9>1JP=!/9WD4D;LDBHZ-MW(Z*Z%64$"T\K
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F "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
